Lilly wins approval for Victoza rival
US-based drug company Eli Lilly has won approval of its GLP-1 analogue Trulicity (dulaglutid) for the US market.
BY BENJAMIN WERNER CHRISTENSEN
Novo Nordisk’s blockbuster diabetes drug, Victoza, can look forward to increased competition in the US in the near future, as the US approval agency, FDA, decided to approve Eli Lilly’s drug dulaglutid on Thursday, Lilly writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Acquisition kickstarted Eli Lilly's oncology focus
For abonnenter
This is Eli Lilly’s focus
For abonnenter
